2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lymphoma, Large B-Cell, Diffuse
2
Turcot syndrome
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Muscle Invasive Bladder Cancer
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Ascites
1
Advanced Solid Tumours
1
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
1
Advanced Solid Malignancies
1
Interventions
tislelizumab
2
Cystectomy
2
vistusertib
1
toripalimab
1
olaparib
1
liposomal doxorubicin
1
durvalumab
1
disitamab vedotin
1
danvatirsen
1
adavosertib
1
Surgical Procedures, Operative
1
Rutin
1
Radiation
1
RC48 antibody
1
Neoadjuvant Therapy
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer
×
danvatirsen
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled